Biosergen AB (publ) (STO:BIOSGN)

Market Cap	19.02M -86.1%
Revenue (ttm)	n/a
Net Income	-40.82M
EPS	-17.38
Shares Out	2.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,903
Open	8.30
Previous Close	8.40
Day's Range	8.10 - 8.30
52-Week Range	8.10 - 66.00
Beta	-0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About Biosergen AB

Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BIOSGN